TP53 mutation and survival in aggressive B cell lymphoma
TP53 is mutated in 20-25% of aggressive B-cell lymphoma (B-NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B-NHL, we investigated TP53 gene mutations within the R...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
14 June 2017
|
| In: |
International journal of cancer
Year: 2017, Jahrgang: 141, Heft: 7, Pages: 1381-1388 |
| ISSN: | 1097-0215 |
| DOI: | 10.1002/ijc.30838 |
| Online-Zugang: | Verlag, kostenfrei, Volltext: http://dx.doi.org/10.1002/ijc.30838 Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.30838 
|
| Verfasserangaben: | Thorsten Zenz, Markus Kreuz, Maxi Fuge, Wolfram Klapper, Heike Horn, Annette M. Staiger, Doris Winter, Hanne Helfrich, Jennifer Huellein, Martin-Leo Hansmann, Harald Stein, Alfred Feller, Peter Möller, Norbert Schmitz, Lorenz Trümper, Markus Loeffler, Reiner Siebert, Andreas Rosenwald, German Ott, Michael Pfreundschuh and Stephan Stilgenbauer |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1577970047 | ||
| 003 | DE-627 | ||
| 005 | 20220814202021.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2017 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/ijc.30838 |2 doi | |
| 035 | |a (DE-627)1577970047 | ||
| 035 | |a (DE-576)507970047 | ||
| 035 | |a (DE-599)BSZ507970047 | ||
| 035 | |a (OCoLC)1341014560 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Zenz, Thorsten |d 1970- |e VerfasserIn |0 (DE-588)114963738 |0 (DE-627)577184202 |0 (DE-576)180278266 |4 aut | |
| 245 | 1 | 0 | |a TP53 mutation and survival in aggressive B cell lymphoma |c Thorsten Zenz, Markus Kreuz, Maxi Fuge, Wolfram Klapper, Heike Horn, Annette M. Staiger, Doris Winter, Hanne Helfrich, Jennifer Huellein, Martin-Leo Hansmann, Harald Stein, Alfred Feller, Peter Möller, Norbert Schmitz, Lorenz Trümper, Markus Loeffler, Reiner Siebert, Andreas Rosenwald, German Ott, Michael Pfreundschuh and Stephan Stilgenbauer |
| 264 | 1 | |c 14 June 2017 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.07.2018 | ||
| 520 | |a TP53 is mutated in 20-25% of aggressive B-cell lymphoma (B-NHL). To date, no studies have addressed the impact of TP53 mutations in prospective clinical trial cohorts. To evaluate the impact of TP53 mutation to current risk models in aggressive B-NHL, we investigated TP53 gene mutations within the RICOVER-60 trial. Of 1,222 elderly patients (aged 61-80 years) enrolled in the study and randomized to six or eight cycles of CHOP-14 with or without Rituximab (NCT00052936), 265 patients were analyzed for TP53 mutations. TP53 mutations were demonstrated in 63 of 265 patients (23.8%). TP53 mutation was associated with higher LDH (65% vs. 37%; p < 0.001), higher international prognostic index-Scores (IPI 4/5 27% vs. 12%; p = 0.025) and B-symptoms (41% vs. 24%; p = 0.011). Patients with TP53 mutation were less likely to obtain a complete remission CR/CRu (CR unconfirmed) 61.9% (mut) vs. 79.7% (wt) (p = 0.007). TP53 mutations were associated with decreased event-free (EFS), progression-free (PFS) and overall survival (OS) (median observation time of 40.2 months): the 3 year EFS, PFS and OS were 42% (vs. 60%; p = 0.012), 42% (vs. 67.5%; p < 0.001) and 50% (vs. 76%; p < 0.001) for the TP53 mutation group. In a Cox proportional hazard analysis adjusting for IPI-factors and treatment arms, TP53 mutation was shown to be an independent predictor of EFS (HR 1.5), PFS (HR 2.0) and OS (HR 2.3; p < 0.001). TP53 mutations are independent predictors of survival in untreated patients with aggressive CD20+ lymphoma. TP53 mutations should be considered for risk models in DLBCL and strategies to improve outcome for patients with mutant TP53 must be developed. | ||
| 650 | 4 | |a DLBCL | |
| 650 | 4 | |a p53 | |
| 650 | 4 | |a R-CHOP | |
| 650 | 4 | |a TP53 mutation | |
| 700 | 1 | |a Hüllein, Jennifer |e VerfasserIn |0 (DE-588)1096556359 |0 (DE-627)856940941 |0 (DE-576)468079610 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cancer |d Bognor Regis : Wiley-Liss, 1966 |g 141(2017), 7, Seite 1381-1388 |h Online-Ressource |w (DE-627)269532781 |w (DE-600)1474822-8 |w (DE-576)079876129 |x 1097-0215 |7 nnas |a TP53 mutation and survival in aggressive B cell lymphoma |
| 773 | 1 | 8 | |g volume:141 |g year:2017 |g number:7 |g pages:1381-1388 |g extent:8 |a TP53 mutation and survival in aggressive B cell lymphoma |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/ijc.30838 |x Verlag |x Resolving-System |z kostenfrei |3 Volltext |
| 856 | 4 | 0 | |u https://onlinelibrary.wiley.com/doi/abs/10.1002/ijc.30838 |x Verlag |z kostenfrei |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20180726 | ||
| 993 | |a Article | ||
| 994 | |a 2017 | ||
| 998 | |g 1096556359 |a Hüllein, Jennifer |m 1096556359:Hüllein, Jennifer |p 9 | ||
| 998 | |g 114963738 |a Zenz, Thorsten |m 114963738:Zenz, Thorsten |d 910000 |d 910100 |e 910000PZ114963738 |e 910100PZ114963738 |k 0/910000/ |k 1/910000/910100/ |p 1 |x j | ||
| 999 | |a KXP-PPN1577970047 |e 3019561116 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"8 S."}],"relHost":[{"title":[{"subtitle":"publication of the International Union against Cancer (UICC) = Journal international du cancer","title":"International journal of cancer","title_sort":"International journal of cancer"}],"pubHistory":["1.1966 -"],"titleTranslated":[{"translated":"Journal international du cancer"}],"titleAlt":[{"title":"Predictive oncology"}],"part":{"pages":"1381-1388","issue":"7","year":"2017","extent":"8","volume":"141","text":"141(2017), 7, Seite 1381-1388"},"disp":"TP53 mutation and survival in aggressive B cell lymphomaInternational journal of cancer","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 28.02.08","Darin: Predictive oncology"],"recId":"269532781","language":["eng"],"corporate":[{"role":"isb","roleDisplay":"Herausgebendes Organ","display":"International Union against Cancer"}],"origin":[{"dateIssuedDisp":"1966-","dateIssuedKey":"1966","publisher":"Wiley-Liss","publisherPlace":"Bognor Regis"}],"id":{"eki":["269532781"],"doi":["10.1002/(ISSN)1097-0215"],"zdb":["1474822-8"],"issn":["1097-0215"]},"physDesc":[{"extent":"Online-Ressource"}]}],"name":{"displayForm":["Thorsten Zenz, Markus Kreuz, Maxi Fuge, Wolfram Klapper, Heike Horn, Annette M. Staiger, Doris Winter, Hanne Helfrich, Jennifer Huellein, Martin-Leo Hansmann, Harald Stein, Alfred Feller, Peter Möller, Norbert Schmitz, Lorenz Trümper, Markus Loeffler, Reiner Siebert, Andreas Rosenwald, German Ott, Michael Pfreundschuh and Stephan Stilgenbauer"]},"origin":[{"dateIssuedKey":"2017","dateIssuedDisp":"14 June 2017"}],"id":{"eki":["1577970047"],"doi":["10.1002/ijc.30838"]},"note":["Gesehen am 26.07.2018"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"recId":"1577970047","language":["eng"],"person":[{"given":"Thorsten","family":"Zenz","role":"aut","roleDisplay":"VerfasserIn","display":"Zenz, Thorsten"},{"roleDisplay":"VerfasserIn","display":"Hüllein, Jennifer","role":"aut","family":"Hüllein","given":"Jennifer"}],"title":[{"title_sort":"TP53 mutation and survival in aggressive B cell lymphoma","title":"TP53 mutation and survival in aggressive B cell lymphoma"}]} | ||
| SRT | |a ZENZTHORSTTP53MUTATI1420 | ||